Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — FY2023 Earnings Presentation
29 slides from Laboratorio Reig Jofre's earnings presentation, 2024
Slide 1: 2023 Results, Future Prospects
2023 RESULTS FUTURE PROSPECTS WEBCAST
Slide 2: Declaration
DECLARATION This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presenta
Slide 3: Table of Contents
TABLE OF CONTENTS REIG JOFRE FINANCIAL KEY MILESTONES TODAY FIGURES AND FUTURE 2023 in figures OUTLOOK Reig Jofre today Reig Jofre 2013 – 2023 Our history ESG Strategic evolution 2023 Sales 2024 outlook International A look into the future performance Evolution/transition Pharmaceutical towards adva
Slide 4: Reig Jofre Today
REIG JOFRE TODAY RJF TODAY Reig Jofre today Our history 2023 Sales International performance Pharmaceutical Technologies Specialty Pharmacare Consumer Healthcare FINANCIAL INFORMATION → FY 2023 figures → Reig Jofre 2013 – 2023 → ESG KEY MILESTONES AND FUTURE Sed ut perspiciatis PROSPECTS → Strategic
Slide 5: Reig Jofre Today
REIG JOFRE TODAY Global benchmark in essential With an extensive And with solid financial solutions for the health of everyone international track record results to back us up 95 years of history Revenues 2023 by country €316 M sales in 2023, +17% Asia 8% Diversified product Rest of UE Oceania 1% po
Slide 6: Reig Jofre - The Story
REIG JOFRE - THE STORY • RJ Poland • EU agreement to reserve • New Injectables plant in vaccine production capacity Food Barcelona supplements Osteoarticular • Sweden plant expansion 2023 • Merger with 2021 Natraceutical • Acquisition of Prescription and BioIbérica OTC Derma & • IPO 2022 Respiratory
Slide 7: Reig Jofre Sales 2023
REIG JOFRE SALES 2023 PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC / Energy / Stress and sleep / Injectables / Lyophilised Dermatology Weight control / Beauty 44 % € 138.7 M +11% 33% €105.1 M +31% 23% €72.3 M +10% The global demand for antibio
Slide 8: International Performance
INTERNATIONAL Rest of Rest of TOTAL Sed PRESENCE ut perspiciatis SALES 2023 Sed ut perspiciatis PERFORMANCE SPAIN EUROPE WORLD +70 COUNTRIES €316 M 45% €141.1 M 43% €137.7 M 12% €37.3 M → All geographic areas +19% +8% +47% DIRECT SALES increased sales over 2022 → The other European markets 8 COUNTRI
Slide 9: International Milestone
2013 We began specific development for the Japanese market INTERNATIONAL 2016 We initiated the commercialization of injectable anesthetics in Japan MILESTONE 2019 We reached 5 million treatments, and by 2023, we reached 15 million Surpassing 15 Million treatments - October 27, 2023 Barcelona, Spain
Slide 10: Pharmaceutical Technologies in 2023
PHARMACEUTICAL TECHNOLOGIES IN 2023 22% Development and 78% Product Developed by PHARMACEUTICAL TECHNOLOGIES 44% Manufacturing REIG JOFRE MANUFACTURING IN-HOUSE COMMERCIAL LICENSING DISTRIBUTION Antibiotics € 139 M CDMO NETWORK AGREEMENTS Injectables / Lyophilised +11% €31 M €36 M €72 M +29 % +3% +1
Slide 11: EU FAB Project to ensure vaccine manufacturing capacity
EU FAB PROJECT to ensure vaccine manufacturing and supply capacity in Europe in the event of a health emergency Agreement signed on July 1, 2023 (4 years) with the European Commission European Commission: Health Emergency Preparedness and Response Authority – HERA EVER-WARM REIG JOFRE, formulation a
Slide 12: Specialty Pharmacare in 2023
SPECIALTY PHARMACARE IN 2023 12% 88% SPECIALTY PHARMACARE 33% Manufacturing Product Developed by REIG JOFRE Osteoarticular € 105 M MANUFACTURING IN-HOUSE COMMERCIAL LICENSING DISTRIBUTION Dermatology +31% CMO NETWORK AGREEMENTS €12 M €80 M €13 M Osteoarticular Other Specialties 11% +50 % +19 % +160
Slide 13: Specialty Pharmacare International
SPECIALTY PHARMACARE INTERNATIONAL RJ Sweden SPECIALTY PHARMACARE 33% → 2009 acquisition of BIOGLAN A.B. Osteoarticular Dermatology €105 M → Increases its production capacity for enteral gels +31% → Grows by +21% in sales compared to '22. 98 → New developments in dermatology Sweden Team and portfoli
Slide 14: Consumer Healthcare in 2023
CONSUMER HEALTHCARE IN 2023 CONSUMER HEALTHCARE 23% 14 OTC / Energy / Stress and sleep € 72 M #1 Ranking / Weight control / Beauty +10% FORTÉ PHARMA Respiratory / €60 M IN PARAPHARMACY IN Weight ENT 83% FRANCE control 17% 11% Other OTC 10% Energy 28% Health 34% REST OF THE REST OF WORLD #1 Ranking S
Slide 15: Forté Pharma
FORTÉ PHARMA CONSUMER HEALTHCARE 23% Brand Consolidation → → #1 brand ranking in Parapharmacy in France. #8 ranking in dietary supplements in France. OTC / Energy / Stress and sleep € 72 M → Growing market for dietary supplements. / Weight control / Beauty +10% → Post-pandemic consumers prioritize p
Slide 16: Financial Data
FINANCIAL DATA RJF TODAY → Reig Jofre today → Our history → 2023 Sales → International performance → Pharmaceutical Technologies → Specialty Pharmacare → Consumer Healthcare FINANCIAL INFORMATION FY 2023 figures Reig Jofre 2013 – 2023 ESG KEY MILESTONES AND FUTURE Sed ut perspiciatis PROSPECTS → Str
Slide 17: 2023 in Figures
2023 IN FIGURES million € REVENUE GROSS MARGIN → Record revenue growth +17%, with all +17% +15 % 316 business areas growing at double-digit rates 271 182 158 → 55% of business sales international → Gross margin grew 15%, impacted by raw 2022 2023 2022 2023 material cost increases EBITDA NET RESULT →
Slide 18: 2023 Assets and Investment
2023 ASSETS INVESTMENT 2023 ASSETS LIABILITIES €12.5 M 198M NON - 204MEQUITY INDUSTRIAL CAPEX 10,6 M CURRENT I+D CAPITALIZATION ASSETS 1,9 M NON-FINANCIAL LIABILITIES 6M → Investment in industrial assets aimed at increasing productivity and capacity continues in 2023 69M WORKING CAPITAL 56M NET FINA
Slide 19: 2023 Liabilities and Financial Debt
2023 LIABILITIES FINANCIAL DEBT 2023 ASSETS LIABILITIES NET FINANCIAL DEBT NET DEBT / EBITDA 198M NON - 204MEQUITY 2023 €55.8 M 2023 1.6x CURRENT 2022 €64.2 M 2022 2.0x ASSETS GROSS FINANCIAL DEBT NON-FINANCIAL LIABILITIES 6M DEBT LEASES APPLICATION OF IFRS 16 9.8 M €61.3M 69M 56M 51.5 M DEBT WITH C
Slide 20: Reig Jofre 2013 - 2023
REIG JOFRE 2013 - 2023 REVENUES 12% EXPENSE AND INVESTMENT IN I+D NET FINANCIAL DEBT Million € CAGR Million € Million € 10% 316 16,4 CAGR 69,0 271 13,9 62,4 236 55,8 230 11,8 52,6 55,1 200 10,6 10,9 11,5 180 9,9 161 168 9,1 155 157 118 6,5 6,6 6,6 29,4 24,5 16,1 18,3 13,9 8,6 2013 2014 2015 2016 201
Slide 21: Reig Jofre ESG 2023 Sustainability
REIG JOFRE ESG 2023 SUSTAINABILITY ENVIRONMENT SOCIAL GOVERNANCE CO2 emissions Sustainability Plan Circular economy People Community European Green Taxonomy Use of resources Risk plan CO2 emissions Water consumption Culture & Engagement Sustainability 2,584 –10% 59% +7% Start of Sustainability Strat
Slide 22: Reig Jofre ESG 2023
REIG JOFRE ESG 2023 → More sustainable energy model, prioritising the use of renewable energy sources → Installation of photovoltaic panels in Toledo and Barcelona → Forecast of reduction in power consumption → Toledo, 12% → Barcelona, 7% TOLEDO BARCELONA 22
Slide 23: Key Milestones and Future Prospects
KEY MILESTONES AND FUTURE PROSPECTS RJF TODAY → Reig Jofre today → Our history → 2023 Sales → International performance → Pharmaceutical Technologies → Specialty Pharmacare → Consumer Healthcare FINANCIAL INFORMATION → FY 2023 figures → Reig Jofre 2013 – 2023 → ESG KEY MILESTONES AND FUTURE Sed ut p
Slide 24: Update: Relevant Milestones 2023
RELEVANT MILESTONES 2023 INVESTMENT INITIAL PLAN Period Period to MAKE PROFITABLE €150 M 2015-2019 2020-2025 New Period to MAKE INTANGIBLES TO BE PROFITABLE VALUED UPDATE Better INVESTMENT POSITIONING Period 2015-2019 2020-2021 2022-2027 24
Slide 25: 2024 Outlook
2024 OUTLOOK We continue to anticipate growth across various business areas, particularly in products and services with higher gross margins: → Growth in demand for antibiotics with recognition of pricing for critical medications in Europe. → Expansion in injectables and lyophilized products as we u
Slide 26: A Look into the Future
A LOOK INTO GROWTH STRATEGIES THE FUTURE to bring our health solutions to more people... INTERNATIONALIZATION. → Opening direct operations with subsidiaries / Joint Ventures in selected markets. → Consolidation of the 3 business units in each market. → Growth through current and new partners in mark
Slide 27: Evolution/Transition towards Advanced Services in Emerging Therapies
EVOLUTION/TRANSITION TOWARDS ADVANCED SERVICES IN EMERGING THERAPIES CHEMICAL BIOLOGICAL Terapiaand CELLULAR products therapies CELULAR GENETIC y Therapy GÉNICA NEW EMERGING → A European leader in our know-how and THERAPEUTIC AREAS cutting-edge technology in the field of injectables. → We provide in
Slide 28: Links and Additional Information
LINKS AND ADDITIONAL INFORMATION → RESULTS WEBCAST https://reigjofre.com/es/inversores/webcasts/ https://reigjofre.com/es/inversores/presentaciones/ → SUBSCRIPTION CENTRE http://www.reigjofre.com/es/noticias/centro-suscripcion → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre.co
Slide 29: Thank You
2023 THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com